• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2023.18003

Assessment of plasminogen activator inhibitor-1 in patients with carbohydrate exchange impairments

[Original research] [Internal diseases]
Dilyara Nailevna Isakova; Elena Feliksovna Doroneva; Albert Akhmetovich Kurmangulov; Aslan Baradinovich Dagaev; Anastasia Frantseva; Ivan Mikhailovich Petrov;

Plasminogen activator inhibitor-1 is a marker of fibrinolysis ineffectiveness, considered as a predictor of cardiovascular risk in patients with disorders of carbohydrate metabolism. An open clinical controlled prospective study of 110 patients with carbohydrate metabolism disorders was carried out to investigate the relationship of a plasminogen activator inhibitor-1 with clinical and metabolic parameters in patients with carbohydrate metabolism disorders and to assess its contribution to the formation of a high cardiovascular risk in this category of patients. The study demonstrated the association of PAI-1 with traditional cardiovascular risk factors, as well as a persistently increased level of 1.4 times PAI-1 (p<0.05) in the group of patients with clinically manifest CVD. This allows us to consider this marker as an additional, in the complex of diagnostic measures in patients with type 2 diabetes.

Download

References:
1. Shestakova M. V., Vikulova O. K., Zheleznyakova A. V., Isakov M. A., Dedov I. I. Diabetes epidemiology in russia: what has changed over the decade? Terapevticheskii arkhiv. – Therapeutic Archive. 2019;91(1):4-13. (In Russ.). https://doi.org/10.26442/00403660.2019.10.000364
3. Strain W. D., Paldánius P. M. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc. Diabetol. 2018;17(1):57. https://doi.org/10.1186/s12933-018-0703-2
4. Norhammar A. Diabetes and cardiovascular mortality: the impact of sex. Lancet Diabetes Endocrinol. 2018;6(7):517-519. https://doi.org/10.1016/S2213-8587(18)30111-6
5. Dedov I. I., Shestakova M. V., Mayorov A. Yu., Shamkhalova M. Sh., Sukhareva O. Yu. [et al.]. Type 2 diabetes mellitus in adults. Sakharnii diabet. – Diabetes mellitus. 2020;23(2S):4-102. (In Russ.). https://doi.org/10.14341/DM12507
6. Avogaro A., Fadini G. P. Microvascular complications in diabetes: A growing concern for cardiologists. Int. J. Cardiol. 2019;291:29-35. https://doi.org/10.1016/j.ijcard.2019.02.030
7. Patel K., Horak H., Tiryaki E. Diabetic neuropathies. Muscle Nerve. 2021;63(1):22-30. https://doi.org/10.1002/mus.27014
8. Cosentino F., Grant P. J., Aboyans V., Bailey C. J., Ceriello A. [et al.]. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur. Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486
9. Giraldo-Grueso M., Echeverri D. From Endothelial Dysfunction to Arterial Stiffness in Diabetes Mellitus. Curr. Diabetes Rev. 2020;16(3):230-237. https://doi.org/10.2174/1573399814666181017120415
10. Goligorsky M. S. Vascular endothelium in diabetes. Am. J. Physiol. Renal Physiol. 2017;312(2):F266-F275. https://doi.org/10.1152/ajprenal.00473.2016
11. Jung R. G., Simard T., Labinaz A., Ramirez F. D., Di Santo P. [et al.]. Role of plasminogen activator inhibitor-1 in coronary pathophysiology. Thromb. Res. 2018;164:54-62. https://doi.org/10.1016/j.thromres.2018.02.135
12. Srikanthan K., Feyh A., Visweshwar H., Shapiro J. I., Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int. J. Med. Sci. 2016;13(1):25-38. https://doi.org/10.7150/ijms.13800
13. Koca N., Ayar K., Bal Ö., Ersoy C. The evaluation of the role of BMI and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients. Minerva Endocrinol. (Torino). 2021;46(1):116-123. https://doi.org/10.23736/S2724-6507.20.03158-2
14. Perkins J. M., Joy N. G., Tate D. B., Davis S. N. Acute effects of hyperinsulinemia and hyperglycemia on vascular inflammatory biomarkers and endothelial function in overweight and obese humans. Am. J. Physiol. Endocrinol. Metab. 2015;309(2):E168-76. https://doi.org/10.1152/ajpendo.00064.201

Keywords: plasminogen activator inhibitor-1, PAI-1, carbohydrate metabolism disorders, type 2 diabetes mellitus, cardiovascular risk